^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CD371-YSNVZ-IL18 CAR T cells
i
Other names: CD371-YSNVZ-IL18 CAR T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Memorial Sloan-Kettering Cancer Center
Drug class:
CLL-1-targeted CAR-T immunotherapy
Related drugs:
10d
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=15, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Dec 2026
Trial completion date • Trial primary completion date
|
FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • IL18 (Interleukin 18) • CD37 (CD37 Molecule)
|
FLT3-ITD mutation • IDH1 mutation • IDH2 mutation
|
CD371-YSNVZ-IL18 CAR T cells
almost3years
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=6, Recruiting, Memorial Sloan Kettering Cancer Center
New P1 trial • CAR T-Cell Therapy
|
FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • IL18 (Interleukin 18) • CD37 (CD37 Molecule)
|
FLT3-ITD mutation • IDH1 mutation • IDH2 mutation • CD37 expression
|
CD371-YSNVZ-IL18 CAR T cells
Share via
